Apr 16, 2019

An Interview with Dr. Joan Mannick of resTORbio

Posted by in categories: biotech/medical, life extension

A number of companies are studying and commercializing rapamycin and rapalogs, including resTORbio, a Boston-based company. Tam Hunt got in touch with Dr. Joan Mannick from the company to find out more about this promising anti-aging therapeutic.

Blagoskonny ([3], [4]) has suggested that rapamycin and rapalogs are effective anti-aging therapies today for humans as well as other animals because they arrest “quasi-programmed hypertrophy.” What are your thoughts on Blagoskonny’s theory?

I think Blagoskonny’s theory is very interesting. mTOR stimulates cell growth, and there is data that mTOR becomes hyperactive in some aging tissues. This may explain why TORC1 inhibitors have benefit in aging-related diseases.

Read more

Comments are closed.